This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Atrial Fibrillation
and you are
between 18 and 85
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The aim of the study is to find out whether aliskiren reduces atrial fibrillation burden measured with a pacemaker device

Provided treatments

  • Drug: aliskiren

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02909166. The sponsor of the trial is Mika Lehto and it is looking for 70 volunteers for the current phase.
Official trial title:
Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF. A Double-blind, Randomized, Parallel-group, Single Centre Study